SNDX - Syndax Pharmaceuticals Inc
IEX Last Trade
13.09
-4.900 -37.433%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:00:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
$17.99
-4.90
-27.24%
Fundamental analysis
29%
Profitability
38%
Dept financing
4%
Liquidity
75%
Performance
15%
Performance
5 Days
-0.08%
1 Month
-21.88%
3 Months
-27.47%
6 Months
-33.11%
1 Year
-37.58%
2 Year
-44.48%
Key data
Stock price
$13.09
DAY RANGE
$13.37 - $17.99
52 WEEK RANGE
$13.15 - $25.34
52 WEEK CHANGE
-$39.69
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
Company detail
CEO: Michael A. Metzger
Region: US
Website: syndax.com
Employees: 110
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: syndax.com
Employees: 110
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Syndax Pharmaceuticals, Inc. develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein.
Recent news